Active — Not RecruitingNot Applicable

Special Use - Results Surveillance on Long-term Use With Wegovy®

Japan1,071 participantsStarted 2024-06-11

Plain-language summary

The purpose of the study is to investigate the safety and effectiveness of Wegovy® in patients with obesity disease under real-world clinical practice in Japan. Participants will get Wegovy® as prescribed by the study doctor. The study will last for about 4 years. Participant will be in the study for about 2 years (104 weeks).

Who can participate

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion criteria

✓. Body mass index (BMI)\* greater than or equal to 27 kilograms per meter square (kg/m\^2) with two or more obesity-related comorbidities\*\*, or
✓. BMI\* greater than or equal to 35 kg/m\^2

What they're measuring

Number of Adverse Reactions (ARs)

Timeframe: From baseline (week 0) to end of study (week 104)

Trial details

NCT IDNCT06283667

SponsorNovo Nordisk A/S

Sponsor typeINDUSTRY

Study typeOBSERVATIONAL

Primary completion2028-01-31

View on ClinicalTrials.gov More Obesity trials